Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Coya Therapeutics, Inc. (NASDAQ:COYA) have received a consensus rating of “Moderate Buy” from the seven ratings firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $15.3333.

Several brokerages have recently weighed in on COYA. D. Boral Capital reaffirmed a “buy” rating and set a $15.00 price target on shares of Coya Therapeutics in a research note on Friday, April 10th. Roth Capital started coverage on shares of Coya Therapeutics in a research report on Friday, June 5th. They issued a “buy” rating and a $12.00 price objective on the stock. Wall Street Zen cut shares of Coya Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Friday, July 17th. Finally, Chardan Capital reiterated a “buy” rating and issued a $14.00 price target on shares of Coya Therapeutics in a research note on Friday, June 12th.

Coya Therapeutics Price Performance

COYA opened at $4.25 on Monday. The company has a market capitalization of $99.70 million, a price-to-earnings ratio of -3.70 and a beta of 0.51. The business’s 50-day moving average price is $4.95 and its two-hundred day moving average price is $4.69. Coya Therapeutics has a 1 year low of $3.71 and a 1 year high of $7.75.

Coya Therapeutics (NASDAQ:COYA) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.07. The company had revenue of $0.25 million during the quarter, compared to analysts’ expectations of $0.15 million. Coya Therapeutics had a negative return on equity of 55.86% and a negative net margin of 266.10%. Sell-side analysts anticipate that Coya Therapeutics will post -1.49 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Coya Therapeutics

Several hedge funds have recently modified their holdings of COYA. Alyeska Investment Group L.P. acquired a new position in shares of Coya Therapeutics during the 4th quarter worth approximately $4,640,000. AWM Investment Company Inc. bought a new stake in shares of Coya Therapeutics during the 4th quarter worth approximately $4,205,000. Private Management Group Inc. acquired a new stake in shares of Coya Therapeutics in the 4th quarter valued at approximately $1,626,000. Marshall Wace LLP boosted its holdings in shares of Coya Therapeutics by 438.8% in the 4th quarter. Marshall Wace LLP now owns 225,358 shares of the company’s stock valued at $1,307,000 after buying an additional 183,533 shares during the last quarter. Finally, Dauntless Investment Group LLC grew its stake in shares of Coya Therapeutics by 199.5% in the third quarter. Dauntless Investment Group LLC now owns 153,021 shares of the company’s stock valued at $872,000 after buying an additional 101,932 shares in the last quarter. Institutional investors own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.